CryoLife, Inc.

Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024. GAAP net income was $2.4 million, or $0.05 per fully diluted share, in the fourth quarter of 2025, versus a net loss of $(16.5) million, or $(0.39) per fully diluted share in the fourth quarter of 2024. For the full year 2025, GAAP net income was $9.8 million, versus a net loss of $(13.4) million for the full year 2024. Adjusted revenue1 was $118.3 million in the fourth quarter of 2025, an increase of 18% on an adjusted constant currency basis compared to the fourth quarter of 2024. Adjusted revenue1 was $443.6 million for the full year 2025, an increase of 13% on an adjusted constant currency basis compared to the full year of 2024. Non-GAAP net income was $8.6 million, or $0.17 per fully diluted share in the fourth quarter of 2025. For the full year, non-GAAP net income was $29.7 million. Adjusted EBITDA increased 29% to $22.7 million in the fourth quarter of 2025 compared to $17.6 million in the fourth quarter of 2024. For the full year adjusted EBITDA increased 26% to $89.6 million. Positive new clinical data from Endospan's NEXUS TRIOMPHE IDE trial presented at the STS Annual Meeting demonstrate high patient survival with low morbidity. Filed the fourth and final module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prothesis. ATLANTA, Feb. 12, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the fourth quarter and year ended December 31, 2025. "We are very pleased with our strong performance for the full year 2025 as we drove 13% adjusted constant currency revenue growth and 26% adjusted EBITDA growth, while making substantial progress in advancing our Aortic focused product development pipeline. Our success continued through the fourth quarter, during which revenue growth was driven by year-over-year growth in stent grafts of 44%, On-X of 25%, and preservation services of 6%, all compared to the fourth quarter of 2024. On an adjusted constant currency basis, fourth quarter year-over-year stent grafts, On-X, and preservation services, grew 36%, 24%, and 6% respectively," said Pat Mackin, Chairman, President, and Chief Executive Officer. Mr. Mackin continued, "We were also pleased to see Endospan present positive new clinical data for its NEXUS TRIOMPHE IDE trial at the Society of Thoracic Surgery Annual Meeting. These results highlighted 94% patient survival from lesion-related death with 91% of patients remaining free from disabling stroke at 1-year post treatment in this high-risk patient group. Also at STS, we saw positive new 2-year data from the AMDS PERSEVERE IDE trial, which further demonstrate persistent clinical benefits of our novel AMDS technology." Mr. Mackin concluded, "Entering 2026, we expect to build on our strong financial performance and continued clinical and operational achievements, reinforcing our confidence in our ability to deliver sustained double-digit constant currency revenue growth and adjusted EBITDA growth at twice the pace of constant currency revenue growth over the long-term." Fourth Quarter 2025 Financial Results Total revenues for the fourth quarter of 2025 were $116.0 million compared to $97.3 million in the fourth quarter of 2024. Adjusted revenues1 for the fourth quarter of 2025 were $118.3 million, an increase of 18% on an adjusted constant currency basis. Net income for the fourth quarter of 2025 was $2.4 million, or $0.05 per fully diluted common share, compared to net loss of $(16.5) million, or $(0.39) per fully diluted common share for the fourth quarter of 2024. Non-GAAP net income for the fourth quarter of 2025 was $8.6 million, or $0.17 per fully diluted common share, compared to non-GAAP net income of $0.2 million, or $0.00 per fully diluted common share for the fourth quarter of 2024. Non-GAAP net income for the fourth quarter of 2025 includes pretax losses related to foreign currency revaluation of less than $0.1 million. Full Year 2025 Financial Results Total revenues for 2025 were $441.3 million compared to $388.5 million for the full year of 2024. Adjusted revenues1 for the full year of 2025 were $443.6 million, an increase of 13% on an adjusted constant currency basis. Net income for 2025 was $9.8 million, or $0.21 per fully diluted common share, compared to net loss of $(13.4) million, or $(0.32) per fully diluted common share for the full year of 2024. Non-GAAP net income for the full year of 2025 was $29.7 million, or $0.63 per fully diluted common share, compared to non-GAAP net income of $10.8 million, or $0.25 per fully diluted common share for the full year of 2024. Non-GAAP net income for the full year of 2025 includes pretax gains related to foreign currency revaluation of $7.2 million. 2026 Financial Outlooks Artivion expects revenues for the full year 2026 to be in the range of $486 to $504 million, representing growth of 10% to 14% on an adjusted constant currency basis compared to 2025 adjusted revenues1. This guidance contemplates currency to be approximately neutral for the full year. Additionally, Artivion expects adjusted EBITDA growth of between 18% and 22% for the full year 2026 compared to 2025, resulting in an expected range of $105 to $110 million for 2026. The Company's financial performance for 2026 and future periods is subject to the risks identified below. Non-GAAP Financial Measures This press release contains non-GAAP financial measures, including non-GAAP adjusted revenue, non-GAAP net income, EBITDA, adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP adjusted revenues reflect an adjustment to GAAP revenue for the impact of certain estimated Italian payback obligations recorded in the fourth quarter of 2025 for fiscal years 2019 through 2025. The Company's non-GAAP adjusted constant currency growth rates compare current year revenues to prior period revenues adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income, EBITDA, adjusted EBITDA, general, administrative, and marketing, and free cash flows results primarily exclude (as applicable) the impact of certain estimated Italian payback reserves recorded in the fourth quarter of 2025 for fiscal years 2019 through 2025, depreciation and amortization expense, interest income and expense, non-cash compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, expense/(income) for business development, integration, and severance, losses on inducement/extinguishment of debt, non-cash interest expense, capital expenditures, and other non-recurring items. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the Company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, the operating expense structure of the Company's existing and acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines, and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and non-cash compensation expense. Company management believes adjusted revenue is a useful metric as it eliminates the impact of the estimated Italian payback obligations recorded in the fourth quarter of 2025 for fiscal years 2019 through 2025 and allows a more direct comparison of our business performance between periods. The Company believes it is useful to exclude this revenue impact and certain expenses from non-GAAP financial measures because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures. The Company's adjusted EBITDA expectations for fiscal 2026 exclude potential charges or gains that may be recorded during the fiscal year, relating to, among other things, non-cash compensation; expense/(income) for business development, integration, and severance; losses on inducement/extinguishment of debt; and foreign currency revaluations. The Company does not attempt to provide reconciliations of forward-looking adjusted EBITDA to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of the Company's financial performance. Webcast and Conference Call Information The Company will hold a teleconference call and live webcast on February 12, 2026, at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13758212. The live webcast and replay can be accessed by going to the Investors section of the Artivion website at and selecting the heading Webcasts & Presentations. About Artivion, Inc. Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, . Forward-Looking Statements Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, our beliefs and expectations about our revenue, year-over-year growth and growth drivers, earnings, currency impacts, and other financial measures and related information; our anticipated capital needs and capital structure; our beliefs about our competitive advantages and market opportunities; the expected impact on our business of the dynamic trade policy and tariff environment; our expected product mix and business strategy; anticipated quarterly fluctuations in our business; the benefits of receiving IDE approval to initiate our Arcevo LSA pivotal trial; the expected clinical benefits of our AMDS technology as a result of data from our AMDS PERSEVERE and PROTECT trials; our ability to scale our business and expand adjusted EBITDA margins; that our revenues for the full year 2026 will be in the range of $486 to $504 million, representing revenue growth of between 10% to 14% compared to 2025 on an adjusted constant currency basis; that we expect non-GAAP adjusted EBITDA to increase between 18% and 22% for the full year 2026 compared to 2025, resulting in non-GAAP adjusted EBITDA in the range of $105 to $110 million in 2025; and our belief that we will be able to grow adjusted EBITDA at twice the rate of constant currency revenue growth. These forward-looking statements are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including, but not limited to, the unpredictability of the timing and outcome of regulatory decisions and other regulatory developments; risks relating to our international operations; the benefits anticipated from our 2024 credit facility and the 2025 amendments thereto, the Ascyrus Medical LLC transaction and Endospan agreements, and our operational improvements in our tissue and stent graft business may not be achieved at all or at the levels we anticipate or had originally anticipated; the benefits anticipated from our clinical trials and regulatory approvals may not be achieved or achieved on our anticipated timelines; and the benefits anticipated from our expansion into APAC and LATAM may not be achieved or achieved on our anticipated timelines. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2025. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise. SOURCE Artivion, Inc. 21% more press release views with Request a Demo

Rising vascular and cardiac procedures, coupled with outcome-focused care models, are driving steady global demand for advanced vascular sealants. NEWARK, DE, UNITED STATES, February 6, 2026 / EINPresswire.com / -- The global vascular sealant market is entering a phase of structurally driven growth as surgical teams worldwide increasingly prioritize predictable bleeding control, faster procedures, and reduced post-operative complications. According to Future Market Insights (FMI), the market is projected to reach USD 1,850.0 million in 2026 and expand to USD 3,150.0 million by 2036, registering a steady CAGR of 5.5% over the forecast period. Growth is being propelled by the rising volume of vascular, endovascular, and cardiac procedures, alongside the expanding role of sealants as standardized adjuncts rather than discretionary tools. Surgeons are increasingly adopting fibrin-based, collagen-based, PEG-based synthetic, and cyanoacrylate sealants to complement sutures and staples, particularly in high-pressure vascular environments where consistency and speed matter most. The emphasis on intraoperative efficiency and post-procedural outcome reliability has elevated vascular sealants from supportive products to workflow-enabling technologies. Improvements in sealant composition, applicator design, and delivery systems are allowing clinicians to achieve reliable sealing across open, hybrid, and minimally invasive procedures. Explore trends before investing – request a sample report today! https://www.futuremarketinsights.com/reports/sample/rep-gb-31869 Innovation and Strategic Consolidation Reshape Competitive Dynamics Large medical technology firms are strengthening their positions through targeted innovation and acquisitions. In January 2026, Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, enhancing its portfolio of percutaneous vessel closure technologies for large-bore and structural heart procedures. “Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market,” said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics. Baxter International continues to lead the fibrin-based sealant segment, particularly in open vascular and cardiovascular surgery. Johnson & Johnson (Ethicon) and Medtronic are advancing adjunctive sealant solutions aligned with their broader surgical and cardiovascular portfolios. Meanwhile, B. Braun, CSL Behring, and Grifols are expanding biologic and plasma-derived sealant offerings, reinforcing the industry’s shift toward integrated hemostasis and sealing platforms. Hospitals Remain the Primary Demand Engine Demand for vascular sealants is still largely concentrated in hospitals, supported by increasing procedural volumes and the adoption of advanced surgical adjuncts. Sealants are widely used for: • Anastomotic sealing • Graft reinforcement • Needle-hole bleeding control • Adjunct soft-tissue sealing • Access-site management Both open vascular surgery and endovascular or hybrid procedures are contributing to rising utilization, particularly as institutions seek to standardize outcomes and reduce variability in bleeding control. Market Structure and Segment Performance FMI’s bottom-up analysis maps revenues across sealant chemistry, form factor, use case, clinical setting, and end-user categories. Fibrin-based sealants dominate with a 34.0% market share, owing to their biomimetic mechanism and predictable performance in high-pressure arterial and venous settings. These products remain the benchmark for newer synthetic and hybrid formulations. By use case, anastomotic sealing accounts for 36.0% of total demand, reflecting the critical importance of leak prevention at vascular junctions to minimize re-interventions and post-operative complications. The market is segmented by: Chemistry: Fibrin-based, PEG-based synthetic, cyanoacrylates, collagen/gelatin-based, and others Form factor: Liquid, patch, spray/foam, pre-filled applicator kits End user: Hospitals, ambulatory surgery centers, specialty cardiac and vascular centers Regional Growth Patterns Reflect Clinical and Economic Maturity Geographically, the United States holds the largest market share, supported by high intervention volumes, mature cardiovascular infrastructure, and strong adoption of protocol-driven adjunct technologies. The U.S. market is expected to grow at a 5.9% CAGR through 2036. China and Saudi Arabia represent the fastest-growing markets, with projected CAGRs of 6.7% and 6.2%, respectively. In China, rapid expansion of surgical infrastructure and minimally invasive procedures in tertiary hospitals is accelerating sealant adoption. Saudi Arabia’s growth is being driven by healthcare modernization and investment in advanced cardiovascular centers. Germany (4.8% CAGR), the UK (4.6%), France (4.4%), and Japan (3.9%) reflect more controlled but stable growth, shaped by standardized surgical practices, value-based care frameworks, and cautious technology adoption. Outcome Accountability Drives Long-Term Adoption Across regions, the shift toward outcomes-driven and value-based care is reshaping sealant selection criteria. Surgeons and healthcare systems are prioritizing products with proven clinical performance, predictable degradation profiles, and compatibility with existing workflows. Sealants are increasingly evaluated not only for hemostatic efficacy, but also for their impact on recovery time, complication avoidance, and resource utilization. Dive deeper—click here for the comprehensive report. https://www.futuremarketinsights.com/reports/brochure/rep-gb-31869 Competitive Landscape and Recent Developments The competitive environment is defined by versatility, ease of use, and applicability across open and minimally invasive procedures. Key players active in the market include Baxter International, Johnson & Johnson (Ethicon), Medtronic, B. Braun, CSL Behring, Grifols, Integra LifeSciences, Artivion (CryoLife), Smith+Nephew, and Teleflex. Ongoing acquisitions and portfolio expansion continue to reinforce the role of vascular sealants as core components of modern surgical infrastructure. Key Players in the Vascular Sealant Market Baxter International Johnson & Johnson (Ethicon) Medtronic B. Braun CSL Behring Grifols Integra LifeSciences Artivion (CryoLife) Smith+Nephew Teleflex Browse Related Reports Vascular Endothelial Growth Factor Inhibitor Market: https://www.futuremarketinsights.com/reports/vascular-endothelial-growth-factor-inhibitor-market Vascular Imaging Systems Market: https://www.futuremarketinsights.com/reports/vascular-imaging-systems-market Vascular Closure Devices Market: https://www.futuremarketinsights.com/reports/vascular-closure-devices-market About Future Market Insights (FMI) Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization trusted by Fortune 500 companies worldwide. With operations in the U.S., UK, India, and Dubai, FMI provides strategic insights across 30+ industries and 1,200+ global markets. Sudip Saha Future Market Insights Inc. +18455795705 ext. email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana. The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group. The data also showed 97% of patients were free from reintervention due to endoleaks with no occurrence of renal failure and one occurrence of paraplegia out to 1-year post-implant. Meanwhile, data from the AMDS PERSEVERE IDE trial demonstrated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry (DANE) tears between 1- and 2-year follow-up. "We are pleased with the 1-year outcomes from the NEXUS TRIOMPHE trial and continued positive results from the AMDS PERSEVERE trial which further validate these important therapeutic options for patients with aortic arch disease," said Pat Mackin, Chairman, President, and Chief Executive Officer at Artivion. 1-Year Data from NEXUS TRIOMPHE IDE Trial: The abstract titled "An Off the Shelf Solution for Chronic Dissections Involving the Aortic Arch: One Year Results of the NEXUS Aortic Arch System" reports 1-year of clinical follow-up on all 94 enrolled patients who were treated with NEXUS for chronic dissection, aneurysm, or other arch disease. The enrolled patients were at high risk for open surgery, as evidenced by ASA risk class III1 (40%) and IV2 (57%). The results demonstrate positive benefits out to 1-year: 94% patient survival from lesion related death in this high-risk study population, 91% of patients were free from disabling stroke, No reinterventions for loss of device integrity, device migration or aortic rupture, 97% of patients were free from reintervention due to endoleaks; and No thrombus formation in the integrated brachiocephalic trunk (BCT) branch. 1ASA class III is defined as severe systemic disease with definite functional limitation 2ASA class IV is defined as severe systemic disease that is a constant threat to life Dr. Himanshu Patel, Professor of Cardiac Surgery and Head of the Section of Adult Cardiac Surgery, University of Michigan, who presented the study results, said, "The 1-year results from the TRIOMPHE study signal a promising path forward for aortic arch treatment with this novel off-the-shelf endovascular stent graft system." 2-Year Data from AMDS PERSEVERE IDE Trial: The abstract titled "Using a Novel Hybrid Aortic Arch Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion: Two-Year Results from the PERSEVERE Trial" reports noteworthy clinical and radiographic outcomes on 93 study participants following 1- and 2-year of clinical and radiographic follow-up. The data continue to demonstrate the clinical benefit of AMDS after 1-year: Minimal additional mortality, limited to 4 deaths due to unrelated cause, No additional unanticipated aortic reoperation, remaining at 4.3%, Continued absence of DANE tears, Stable total aortic diameter in aortic zones 1-6 (aortic arch to upper abdomen), with a mean change of <2mm and continued mean true lumen diameter expansion up to 1.7 mm; and Dr. Kyle Eudailey, Associate Professor at the University of Alabama at Birmingham said, "The 2-year results from the PERSEVERE trial continue to show excellent clinical and radiographic outcomes, demonstrating that AMDS is an important tool in the treatment of acute DeBakey Type I aortic dissection." About the NEXUS TRIOMPHE Clinical Trial The NEXUS TRIOMPHE trial is the US IDE study evaluating the NEXUS device in the endovascular treatment of chronic aortic dissection, either primary type B or residual dissection after prior type A repair, or aneurysm (not reported here). Inclusion criteria include the patient being high risk for open surgical repair. The clinical module of the PMA is anticipated to be filed after completion of one year of follow up with the 54 patients in the chronic aortic dissection statistical primary cohort. About the AMDS PERSEVERE Clinical Trial The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial to determine if patients with acute DeBakey Type I aortic dissection can be treated safely and effectively using the AMDS Hybrid Prosthesis. The trial was designed to support the Company's application for premarket approval (PMA) of the AMDS that is currently under review by the U.S. Food and Drug Administration (FDA). The trial consists of 93 participants in the U.S., who have experienced an acute DeBakey Type I aortic dissection complicated by malperfusion. Each participant will be followed for up to 5 years. 30-day trial data met combined safety and primary efficacy endpoints, demonstrating significant reduction of major adverse events (MAEs), including all-cause mortality, stroke, renal failure requiring dialysis, and myocardial infarction, and distal anastomotic new entry (DANE) tears following AMDS implantation. The secondary endpoint relates to remodeling of the aorta. About Artivion, Inc. Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, . Contacts: SOURCE Artivion, Inc. 21% more press release views with Request a Demo